Technical Analysis for SHPG - Shire plc

Grade Last Price % Change Price Change
grade F 144.99 -0.48% -0.70
SHPG closed down 0.48 percent on Friday, January 19, 2018, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
3 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical SHPG trend table...

Date Alert Name Type % Chg
Jan 19 Lower Bollinger Band Walk Weakness 0.00%
Jan 19 Inside Day Range Contraction 0.00%
Jan 19 Wide Bands Range Expansion 0.00%
Jan 19 Down 3 Days in a Row Weakness 0.00%
Jan 19 Down 4 Days in a Row Weakness 0.00%
Jan 19 Down 5 Days in a Row Weakness 0.00%
Jan 19 Oversold Stochastic Weakness 0.00%
Jan 18 New Downtrend Bearish -0.48%
Jan 18 Lower Bollinger Band Walk Weakness -0.48%
Jan 18 Wide Bands Range Expansion -0.48%

Older signals for SHPG ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). The SP segment offers products for the treatment of attention deficit and hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of ulcerative colitis; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, this segment provides FOSRENOL, a phosphate binder for use in end-stage renal failure patients receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. The HGT segment offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. The RM segment provides DERMAGRAFT, a bio-engineered skin substitute that assists in restoring damaged tissue. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. In addition, it is developing various products in the areas of behavioral health, gastrointestinal, HGT, RM, and other therapeutic areas. The company markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. It has operations in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc was founded in 1986 and is headquartered in Dublin, Ireland.
Is SHPG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 192.15
52 Week Low 137.17
Average Volume 1,168,085
200-Day Moving Average 159.1458
50-Day Moving Average 148.5934
20-Day Moving Average 152.5305
10-Day Moving Average 148.45
Average True Range 3.1919
ADX 26.44
+DI 13.94
-DI 31.34
Chandelier Exit (Long, 3 ATRs ) 150.7943
Chandelier Exit (Short, 3 ATRs ) 151.3957
Upper Bollinger Band 162.1965
Lower Bollinger Band 142.8645
Percent B (%b) 0.11
BandWidth 12.674186
MACD Line -1.2962
MACD Signal Line 0.0547
MACD Histogram -1.3508
Fundamentals Value
Market Cap 43.19 Billion
Num Shares 298 Million
EPS 2.23
Price-to-Earnings (P/E) Ratio 65.02
Price-to-Sales 2.82
Price-to-Book 1.34
PEG Ratio 0.84
Dividend 0.92
Dividend Yield 0.63%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 148.76
Resistance 3 (R3) 148.69 147.37 148.13
Resistance 2 (R2) 147.37 146.41 147.40 147.92
Resistance 1 (R1) 146.18 145.82 145.52 146.25 147.71
Pivot Point 144.86 144.86 144.53 144.89 144.86
Support 1 (S1) 143.67 143.90 143.01 143.74 142.27
Support 2 (S2) 142.35 143.31 142.38 142.06
Support 3 (S3) 141.16 142.35 141.85
Support 4 (S4) 141.23